Skip to content

Invest4 publishers2 min readPublished

Onsemi's $5.7 billion cash bid for Synaptics lands 16% above the market price

Onsemi will pay $123 a share in cash, about $5.7 billion, for Synaptics after a rival bid, replacing a June stock deal valued near $7 billion. The cash price sits 16% above Synaptics' Thursday close, so holders gain on the market even as the headline total shrinks.

The Investor · Invest desk

Photograph accompanying Onsemi's $5.7 billion cash bid for Synaptics lands 16% above the market price
Photo: finance.yahoo.com

What happened

  • Synaptics' board reviewed the amended terms with its financial and legal advisers and unanimously found them in shareholders' best interests.
  • Synaptics shares rose 14% on Friday, the day after the revision, and onsemi's gained about 6%.
  • Onsemi now expects the purchase to add to its non-GAAP earnings per share immediately after closing.
  • The Federal Trade Commission has already approved the deal, and reviews in other jurisdictions are still underway.

Compiled by The InvestorSomething wrong?How this is made

Why it matters

  • cost Onsemi owners now fund the full price with cash and Morgan Stanley debt, so the day-one accretion claim depends on interest costs staying below what Synaptics earns.
  • constraint A counterbidder would have to top a cash offer that already has FTC clearance and committed debt behind it, with no financing condition to test.
  • decision Synaptics shareholders now vote on a fixed cash amount, so their choice turns on whether the rival returns, with onsemi's share price out of the calculation.

A competing bid normally pushes a price up, so a revision that takes about $1.3 billion off the headline needs explaining [1][2]. The June agreement paid Synaptics holders in onsemi stock [3], and onsemi's shares now sit nearly 40% below their June record [5]. Investopedia, in a report carried by Yahoo Finance, said the move to cash may ease doubts that built up after that drop [20]. The sources do not give the exchange ratio, so the old offer's value on Thursday cannot be rebuilt from them. Synaptics' own share price is a cleaner mark. A $123 price at a 16% premium [4] puts Thursday's close near $106 [2]. If the two headline values are on the same basis, the June terms implied about $151 a share [3].

On that evidence, Synaptics' board took certainty and a premium together, measured against a stock offer the market had already marked down. "By transitioning to an all-cash structure, we are providing value certainty at a meaningful premium as compared to current value," Rahul Patel, Synaptics' chief executive, said [18]. The counter-case is the upside his holders hand back. Onsemi stock is up 57% this year even after its slide [19], and a stock with that range could have carried a share-based offer back toward its June value.

Onsemi's chief executive, Hassane El-Khoury, presented the switch as a saving for his own holders. "The all-cash transaction delivers higher value to our shareholders through lower total cost consideration," he said [17]. Bank of America analysts wrote that the terms "could be received more favorably by investors as it removes the dilution overhang while preserving the strategic rationale" [16]. No new onsemi shares go to Synaptics investors [15].

The synergy target did not change. Onsemi still expects at least $200 million a year in run-rate synergies [8], about 3.5% of the $5.7 billion price [4][1]. Revenue synergies and moving part of Synaptics' production in-house come on top, and they start contributing only after the first 18 months post-close [9]. Against a close expected by mid-2027 [11], that puts the insourcing money at around the end of 2028 at the earliest [5]. For the first year and a half, onsemi's case rests on the cost target and the financing.

A counterbid is the clearest way this turns out differently, and the market is pricing it as unlikely. A 14% gain on Friday [13] takes a roughly $106 stock to about $121, some $2 under the cash price on rounded figures [6]. If Synaptics trades above $123 before its shareholders vote [11], the market expects a higher offer and this view is wrong.

What to watch

  • The size and interest rate of onsemi's Morgan Stanley-backed borrowing, set against its promise of immediate non-GAAP EPS accretion.
  • Whether the reviews outside the US clear in time for the mid-2027 closing target.
  • The date and result of the Synaptics shareholder vote, and any disclosure of who made the competing proposal and on what terms.
Loading claim ledger
Loading source directory links
Loading share composer
Loading topic controls
Loading related stories